Statements (84)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Eli_Lilly
gptkb:Loxo_Oncology |
| gptkbp:approves |
gptkb:2020
gptkb:FDA |
| gptkbp:availability |
prescription medication
|
| gptkbp:brand |
gptkb:Retevmo
|
| gptkbp:class |
kinase inhibitor
|
| gptkbp:clinical_trial |
gptkb:STARTRK-1
monotherapy or combination therapy Phase 1/2 LIBRETTO-001 LIBRETTO-321 NC T03037385 ALKA-372-001 NC T02568267 STARTRK-2 |
| gptkbp:contraindication |
hypersensitivity to entrectinib
|
| gptkbp:dosage_form |
gptkb:beer
|
| gptkbp:education |
provided by healthcare providers
|
| gptkbp:effective_date |
2020-11-30
|
| gptkbp:has_ability |
120 mg
40 mg |
| gptkbp:has_programs |
available for eligible patients
|
| https://www.w3.org/2000/01/rdf-schema#label |
Retevmo
|
| gptkbp:indication |
RET fusion-positive solid tumors
RET-altered thyroid cancer NTRK fusion-positive solid tumors |
| gptkbp:ingredients |
gptkb:entrectinib
gptkb:selpercatinib C22 H24 Cl N5 O2 S |
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
L01 XX
|
| gptkbp:is_used_for |
treatment of non-small cell lung cancer
|
| gptkbp:label |
prescription only
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Japan gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
gptkb:beer
bottle of 30 capsules |
| gptkbp:pharmacokinetics |
ongoing
|
| gptkbp:population |
adults
pediatric patients |
| gptkbp:previous_name |
gptkb:battle
|
| gptkbp:price |
varies by location
varies by insurance |
| gptkbp:products |
gptkb:Brigatinib
gptkb:Osimertinib gptkb:Alectinib gptkb:Larotrectinib gptkb:Crizotinib |
| gptkbp:provides_information_on |
included in ESMO guidelines
included in NCCN guidelines |
| gptkbp:receives_funding_from |
supported by Eli Lilly
|
| gptkbp:requires |
available online
|
| gptkbp:research_focus |
personalized medicine
targeted therapy precision medicine oncogenic drivers RET gene alterations |
| gptkbp:safety_features |
adverse event reporting
post-marketing studies recommended during treatment |
| gptkbp:scholarships |
available through manufacturer
|
| gptkbp:side_effect |
fatigue
nausea hypertension vomiting diarrhea constipation elevated liver enzymes increased liver enzymes encouraged for patients |
| gptkbp:social_structure |
C22 H25 N3 O3 S
|
| gptkbp:storage |
store at room temperature
|
| gptkbp:targets |
RET fusion-positive tumors
|
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:weight |
429.97 g/mol
|